The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment.

MLA

Topletz-Erickson, Ariel R., et al. “The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment.” Clinical Pharmacokinetics, vol. 61, no. 12, Dec. 2022, pp. 1761–70. EBSCOhost, https://doi.org/10.1007/s40262-022-01183-6.

APA

Topletz-Erickson, A. R., Lee, A. J., Mayor, J. G., Sun, H., Abdulrasool, L. I., Rustia, E. L., Walker, L. N., & Endres, C. J. (2022). The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment. Clinical Pharmacokinetics, 61(12), 1761–1770. https://doi.org/10.1007/s40262-022-01183-6

Chicago

Topletz-Erickson, Ariel R, Anthony J Lee, JoAl G Mayor, Hao Sun, Layth I Abdulrasool, Evelyn L Rustia, Luke N Walker, and Christopher J Endres. 2022. “The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment.” Clinical Pharmacokinetics 61 (12): 1761–70. doi:10.1007/s40262-022-01183-6.